Literature DB >> 20484960

Pre-diagnostic levels of anionic trypsinogen, cationic trypsinogen, and pancreatic secretory trypsin inhibitor in relation to pancreatic cancer risk.

Dorthe Johansen1, Jonas Manjer, Sara Regner, Björn Lindkvist.   

Abstract

BACKGROUND/AIMS: Experimental studies have suggested that trypsinogen may enhance tumor progression and that the ratio between anionic trypsinogen and cationic trypsinogen (HAT/HCT) and between the sum of trypsinogens and pancreatic secretory trypsin inhibitor (PSTI) ((HAT + HCT)/PSTI) are disturbed in patients with pancreatic cancer. The aim of this study was to investigate if pre-diagnostic levels of these parameters are associated with subsequent pancreatic cancer risk.
METHODS: A total of 33,346 subjects participated in a health screening programme in Malmö, Sweden. Pancreatic cancer cases (n = 84) were matched to three controls each. HAT, HCT and PSTI were analyzed in pre-diagnostic serum samples. Odds ratios for pancreatic cancer were calculated using logistic regression and were then stratified for other risk factors.
RESULTS: In the main analysis, a statistically significant association between the ratio between HAT/HCT and pancreatic cancer was observed for all, for the crude OR and for the ORs adjusted for sex, BMI or Helicobacter pylori. When stratified for sex, statistically significant associations were found for females in the crude OR and for the ORs adjusted for time to analysis, BMI, alcohol consumption or H. pylori. There was a positive association between the ratio of HAT/HCT to pancreatic cancer in the intermediate/high alcohol consumption group and subjects with a BMI <25. The sum of trypsinogens showed a similar pattern, but was only of borderline significance in the intermediate/high alcohol consumption group.
CONCLUSION: Our hypothesis predicted an increased risk for pancreatic cancer related to an imbalance between trypsin activity and trypsin inhibition capacity. The findings concerning the ratio of HAT/HCT are in line with this. The results related to analyses stratified for other risk factors should be considered as mainly explorative. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484960     DOI: 10.1159/000243732

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.

Authors:  Qiang Yi; Feng Dong; Liqing Lin; Qicai Liu; Shu Chen; Feng Gao; Qingliang He
Journal:  Tumour Biol       Date:  2015-11-06

2.  Application of an electrochemical immunosensor with a MWCNT/PDAA modified electrode for detection of serum trypsin.

Authors:  Qiang Yi; Qicai Liu; Feng Gao; Qingquan Chen; Guina Wang
Journal:  Sensors (Basel)       Date:  2014-06-10       Impact factor: 3.576

Review 3.  Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis.

Authors:  Kjetil Søreide; Marcus Roalsø; Jan Rune Aunan
Journal:  J Pancreat Cancer       Date:  2020-02-06

4.  miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.

Authors:  Zhi-Chao Wang; Yan Li; Ke-Liang Wang; Lu Wang; Bo-Sen You; Dan-Feng Zhao; Zhong-Qing Liu; Rui-Zhe Fang; Jia-Qi Wang; Wei Zhang; Jin-Ming Zhang; Wan-Hai Xu
Journal:  Aging (Albany NY)       Date:  2020-07-21       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.